Investigational data for
Lynparza™ (olaparib) tablets in BRCA-mutated
metastatic breast cancer to be highlighted in plenary presentation
of Phase III OlympiAD trial
Key investigational trials show further
evidence of Tagrisso® (osimertinib) effect in
patients with EGFR T790M mutation-positive non-small cell lung
cancer (NSCLC) and central nervous system (CNS) metastases (AURA3
trial) or leptomeningeal disease (BLOOM trial)
New investigational data demonstrate
advances in Immuno-Oncology, including Imfinzi™
(durvalumab) in NSCLC, bladder cancer
AstraZeneca, along with its global biologics research and
development arm, MedImmune, will demonstrate how it is rapidly
delivering on the Company’s science-led strategy for
transformational cancer medicine development at the 2017 American
Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL,
June 2-6.
With three new oncology medicines addressing the unmet needs of
patients with ovarian, lung, and bladder cancers approved in under
three years, AstraZeneca is now halfway to delivering on its
promise to launch six new medicines for cancer by 2020.
This progress is reflected in the 100 company-sponsored and
supported abstracts, including five Best-of-ASCO presentations, 11
oral presentations and eight poster discussions, accepted for the
meeting. These include new data on approved and potential new
medicines from the Company’s pipeline across multiple scientific
platforms and tumor types.
Jamie Freedman, Executive Vice President, Oncology at
AstraZeneca, said: “2017 is a pivotal year for our oncology
portfolio as global launch and development programs for Lynparza,
Tagrisso and Imfinzi gain momentum, with further pivotal data
anticipated in the coming months, in particular in 1st-line
non-small cell lung cancer. We are excited to demonstrate the
strength of our rapidly-expanding portfolio at ASCO, including the
positive OlympiAD results for Lynparza in BRCA-mutated metastatic
breast cancer.”
Growing confidence in DNA Damage Response (DDR) approach
emphasized by OlympiAD results‘Late-breaker’ data from the
OlympiAD trial of olaparib versus chemotherapy in HER2-negative
germline BRCA1 or BRCA2 mutated breast cancer patients (Abstract
#LBA4) are the first positive Phase III results for a poly
ADP-ribose polymerase (PARP) inhibitor beyond ovarian cancer.
They are an important next step in the development of AstraZeneca’s
DDR approach to selectively targeting of tumors through
deficiencies in cancer cell DNA repair mechanisms.
Additional olaparib data will include:
- SOLO-2: Oral presentation of Phase III
data on the relationship between health-related quality of life
(HRQOL) and patient-centered and clinical outcomes with olaparib
maintenance following chemotherapy in patients with BRCA-mutated
platinum-sensitive relapsed serous ovarian cancer (Abstract
#5507)
- Study 19: Randomized Phase II overall
survival and updated progression-free survival data for the
combination of olaparib and cediranib versus olaparib alone in
recurrent platinum-sensitive ovarian cancer (Abstract #5535)
AstraZeneca’s unique DDR pipeline will also be illustrated
through an oral presentation of Phase I data on the WEE1 inhibitor,
AZD1775, in combination with radiation therapy and temozolomide in
patients with newly diagnosed glioblastoma multiforme (GBM) and
evaluation of intratumoral drug distribution in patients with
recurrent GBM (Abstract #2005). Additional information will also be
presented from a Phase I trial of AZD1775 in combination with
neoadjuvant weekly cisplatin and docetaxel in borderline-resectable
head and neck squamous cell carcinoma (HNSCC) (Abstract #6034).
Extended evidence of the effect of osimertinib on CNS
metastasesLatest osimertinib investigational data from the
AURA3 trial to be released during an oral presentation will provide
further evidence of the response to treatment in patients with
epidermal growth factor receptor (EGFR) T790M mutation-positive
non-small cell lung cancer (NSCLC) and central nervous system (CNS)
metastases (Abstract #9005).
Further insights into the ability of osimertinib to cross the
blood-brain barrier will be provided through updated results from
the BLOOM trial of osimertinib in patients with EGFR
mutation-positive NSCLC and leptomeningeal disease (Abstract
#2020).
New data on durvalumab as monotherapy and in
combinationBuilding on exciting recent milestones for its
Immuno-Oncology program, AstraZeneca will be presenting updated
data from the NSCLC and bladder cancer cohorts of the Phase I/II
Study 1108 of durvalumab in patients with advanced solid tumors.
New data in locally advanced or metastatic urothelial carcinoma
(mUC) (Abstract #4525) reinforce the May 2017 US FDA approval of
Imfinzi for the treatment of patients with locally advanced or mUC
who have disease progression during or following
platinum-containing chemotherapy, or whose disease has progressed
within 12 months of receiving platinum-containing chemotherapy
before (neoadjuvant) or after (adjuvant) surgery.
Updated durvalumab monotherapy Study 1108 results in Stage
IIIB/IV NSCLC (Abstract #9085) will also be presented. These data
underline AstraZeneca’s forward momentum in lung cancer following
the positive top-line results of the Phase III PACIFIC trial of
durvalumab as sequential treatment in patients with locally
advanced, unresectable (Stage III) NSCLC. In an oral presentation,
MedImmune will present data on a novel relationship in NSCLC
between EGFR pathway activation and the immunosuppressive molecule
CD73 (Abstract #11505).
LYNPARZA™ (olaparib) IMPORTANT SAFETY
INFORMATION
WARNINGS AND PRECAUTIONS
There are no contraindications for Lynparza.
Myelodysplastic Syndrome/Acute Myeloid Leukemia
(MDS/AML): Occurred in <1% of patients treated with
Lynparza, and the majority of those reports were fatal. The
duration of therapy in patients who developed secondary MDS/AML
varied from <6 months to >2 years. In a randomized
placebo-controlled trial, MDS/AML occurred in 2% of patients
treated with Lynparza. All of these patients had previous
chemotherapy with platinum agents and/or other DNA damaging agents,
including radiotherapy, and some of these patients also had a
history of previous cancer or of bone marrow dysplasia.
Monitor patients for hematological toxicity at baseline and
monthly thereafter. Do not start Lynparza until patients have
recovered from hematological toxicity caused by previous
chemotherapy (≤Grade 1). For prolonged hematological toxicities,
interrupt Lynparza and monitor blood counts weekly until recovery.
If the levels have not recovered to Grade 1 or less after four
weeks, refer the patient to a hematologist for further
investigations, including bone marrow analysis and blood sample for
cytogenetics. Discontinue if MDS/AML is confirmed.
Pneumonitis: Occurred in <1% of patients exposed to
Lynparza, and some cases were fatal. If patients present with new
or worsening respiratory symptoms such as dyspnea, fever, cough,
wheezing, or a radiological abnormality occurs, interrupt treatment
with Lynparza and initiate prompt investigation. Discontinue if
pneumonitis is confirmed.
Embryo-Fetal Toxicity: Lynparza can cause fetal harm. A
pregnancy test should be performed on all pre-menopausal women
prior to treatment. Advise females of reproductive potential of the
potential risk to a fetus and to use effective contraception during
treatment and for six months after receiving the final dose.
ADVERSE REACTIONS
In clinical studies, the most common adverse reactions (Grades
1-4) in ≥20% of patients included anemia (34%), nausea (75%),
fatigue (including asthenia) (68%), vomiting (43%), diarrhea (31%),
dysgeusia (21%), dyspepsia (25%), headache (25%), decreased
appetite (25%), nasopharyngitis/pharyngitis/URI (43%), cough (21%),
arthralgia/musculoskeletal pain (32%), myalgia (25%), back pain
(25%), dermatitis/rash (25%), and abdominal pain/discomfort
(47%).
Common lab abnormalities (Grades 1-4) included decrease in
hemoglobin (90%), decrease in absolute neutrophil count (32%),
decrease in platelets (30%), decrease in lymphocytes (56%), mean
corpuscular volume elevation (85%), and increase in creatinine
(30%).
DRUG INTERACTIONS
Anticancer Agents: Clinical studies of Lynparza in
combination with other myelosuppressive anticancer agents,
including DNA damaging agents, indicate a potentiation and
prolongation of myelosuppressive toxicity.
CYP3A Inhibitors: Avoid concomitant use of strong and
moderate CYP3A inhibitors. If the strong or moderate CYP3A
inhibitor must be co-administered, reduce the dose of Lynparza.
Advise patients to avoid grapefruit and Seville oranges during
Lynparza treatment.
CYP3A Inducers: Avoid concomitant use of strong and
moderate CYP3A inducers when using Lynparza. If a moderate inducer
cannot be avoided, be aware of a potential for decreased efficacy
of Lynparza.
USE IN SPECIFIC POPULATIONS
Lactation: No data are available regarding the presence
of olaparib in human milk, the effects on the breastfed infant or
on milk production. Because of the potential for serious adverse
reactions in the breastfed infant, advise a lactating woman not to
breastfeed during treatment with Lynparza and for one month after
receiving the final dose.
Hepatic Impairment: No dose adjustment is required in
patients with mild hepatic impairment (Child-Pugh classification
A). There are no data in patients with moderate or severe hepatic
impairment.
Renal Impairment: No dosage adjustment is necessary in
patients with mild renal impairment (CLcr 51-80 mL/min). In
patients with moderate renal impairment (CLcr 31-50 mL/min), reduce
the dose to 300 mg twice daily. There are no data in patients with
severe renal impairment or end-stage renal disease (CLcr ≤30
mL/min).
Please see complete Prescribing Information, including
Patient Information (Medication Guide).
TAGRISSO® (osimertinib) IMPORTANT SAFETY
INFORMATION
- There are no contraindications for
Tagrisso
- Interstitial Lung Disease
(ILD)/Pneumonitis occurred in 3.5% and was fatal in 0.6% of 833
Tagrisso-treated patients. Withhold Tagrisso and promptly
investigate for ILD in patients who present with worsening of
respiratory symptoms indicative of ILD (eg, dyspnea, cough,
and fever). Permanently discontinue Tagrisso if ILD is
confirmed
- Heart rate-corrected QT (QTc) interval
prolongation occurred in Tagrisso-treated patients. Of the 833
Tagrisso-treated patients, 0.7% of patients were found to have a
QTc > 500 msec, and 2.9% of patients had an increase from
baseline QTc > 60 msec. No QTc-related arrhythmias were
reported. Conduct periodic monitoring with ECGs and electrolytes in
patients with congenital long QTc syndrome, congestive heart
failure, electrolyte abnormalities, or those who are taking
medications known to prolong the QTc interval. Permanently
discontinue Tagrisso in patients who develop QTc interval
prolongation with signs/symptoms of life-threatening
arrhythmia
- Cardiomyopathy occurred in 1.9% and was
fatal in 0.1% of 833 Tagrisso-treated patients. Left Ventricular
Ejection Fraction (LVEF) decline ≥ 10% and a drop to < 50%
occurred in 4% of 655 Tagrisso-treated patients. Conduct cardiac
monitoring, including an assessment of LVEF at baseline and during
treatment in patients with cardiac risk factors. Assess LVEF in
patients who develop relevant cardiac signs or symptoms during
treatment. For symptomatic congestive heart failure or persistent,
asymptomatic LV dysfunction that does not resolve within 4 weeks,
permanently discontinue Tagrisso
- Keratitis was reported in 0.7% of 833
Tagrisso-treated patients in clinical trials. Promptly refer
patients with signs and symptoms suggestive of keratitis (such as
eye inflammation, lacrimation, light sensitivity, blurred vision,
eye pain, and/or red eye) to an ophthalmologist
- Advise pregnant women of the potential
risk to a fetus. Advise females of reproductive potential to use
effective contraception during Tagrisso treatment and for 6 weeks
after the final dose. Advise males with female partners of
reproductive potential to use effective contraception for 4
months after the final dose
- The most common adverse reactions
(≥20%) in patients treated with Tagrisso were diarrhea (41%), rash
(34%), dry skin (23%), nail toxicity (22%), and fatigue (22%)
INDICATION
Tagrisso is indicated for the treatment of patients with
metastatic epidermal growth factor receptor (EGFR)
T790M mutation-positive non-small cell lung cancer
(NSCLC), as detected by an FDA-approved test, whose
disease has progressed on or after EGFR tyrosine kinase inhibitor
therapy.
Please see complete Prescribing
Information including Patient Information.
IMFINZI™ (durvalumab) IMPORTANT SAFETY
INFORMATION
There are no contraindications for Imfinzi.
Monitor patients for clinical signs and symptoms of
immune-mediated pneumonitis, hepatitis, colitis or diarrhea,
endocrinopathies, nephritis, rash or dermatitis, other
immune-mediated adverse reactions, and infection. Please refer to
the full Prescribing Information for important dose management
information specific to adverse reactions.
Immune-Mediated PneumonitisIn the combined safety
database (n=1414), immune-mediated pneumonitis occurred in 32
patients (2.3%), including 1 fatal case (0.1%) and 6 Grade 3–4
cases (0.4%). In Study 1 (n=182), 1 patient (0.5%) died from
immune-mediated pneumonitis. Monitor patients for signs and
symptoms of pneumonitis and evaluate with radiographic imaging when
suspected. Administer corticosteroids for ≥Grade 2 pneumonitis.
Withhold Imfinzi for Grade 2 pneumonitis; permanently discontinue
for Grade 3–4 pneumonitis.
Immune-Mediated HepatitisIn the combined safety database
(n=1414), immune-mediated hepatitis occurred in 16 patients (1.1%),
including 1 fatal case (<0.1%) and 9 Grade 3 cases (0.6%). Grade
3–4 elevations in ALT occurred in 40/1342 patients (3.0%), AST in
58/1336 patients (4.3%), and total bilirubin in 37/1341 patients
(2.8%). In Study 1 (n=182), 1 patient (0.5%) died from
immune-mediated hepatitis, and 2 patients (1.1%) experienced
immune-mediated hepatitis, including 1 Grade 3 case (0.5%). Monitor
patients for abnormal liver tests in each cycle during treatment
with Imfinzi. Administer corticosteroids and withhold Imfinzi for
Grade 2–3 ALT or AST >3–5X ULN or ≤8X ULN or total
bilirubin >1.5–3X ULN or ≤5X ULN. Permanently discontinue
Imfinzi in patients with Grade 3 ALT or AST >8X ULN or total
bilirubin >5X ULN, or in patients with concurrent ALT or AST
>3X ULN and total bilirubin >2X ULN with no other cause.
Immune-Mediated ColitisIn the combined safety database
(n=1414), immune-mediated colitis or diarrhea occurred in 18
patients (1.3%), including 1 Grade 4 case (<0.1%) and 4 Grade 3
cases (0.3%). In Study 1 (n=182), 23 patients (12.6%) experienced
colitis or diarrhea, including 2 Grade 3–4 cases (1.1%). Monitor
patients for signs and symptoms of colitis or diarrhea. Administer
corticosteroids for ≥Grade 2 colitis or diarrhea. Withhold Imfinzi
for Grade 2 colitis or diarrhea; permanently discontinue for Grade
3–4 colitis or diarrhea.
Immune-Mediated Endocrinopathies
- Immune-mediated thyroid disorders,
adrenal insufficiency, type 1 diabetes mellitus and
hypophysitis/hypopituitarism have occurred with Imfinzi. Monitor
patients for clinical signs and symptoms of endocrinopathies. For
Grade 2–4 endocrinopathies (except hypothyroidism) withhold dose
until clinically stable and offer symptomatic management for
hyperthyroidism. For Grade 2–4 hypothyroidism, initiate thyroid
hormone replacement as needed
- Thyroid disorders— In the combined
safety database (n=1414), immune-mediated hypothyroidism and
hyperthyroidism occurred in 136 patients (9.6%) and 81 patients
(5.7%), respectively. Thyroiditis occurred in 10 patients (0.7%),
including 1 Grade 3 case (<0.1%) in a patient who had a
myocardial infarction. In 9 patients with thyroiditis, transient
hyperthyroidism preceded hypothyroidism. Treatment with a
beta-blocker and/or thioamide was administered for hyperthyroidism
in five of these patients. In Study 1 (n=182), Grade 1–2
hypothyroidism or thyroiditis occurred in 10 patients (5.5%). Grade
1–2 hyperthyroidism or thyroiditis leading to hyperthyroidism
occurred in 9 patients (4.9%). Monitor patients for abnormal
thyroid function tests prior to and periodically during
treatment
- Immune-mediated adrenal
insufficiency—In the combined safety database (n=1414),
immune-mediated adrenal insufficiency occurred in 13 patients
(0.9%), including 2 Grade 3 cases (0.1%). In Study 1 (n=182), Grade
1 adrenal insufficiency occurred in 1 patient (0.5%). Administer
corticosteroids and hormone replacement as clinically
indicated
- Type 1 diabetes mellitus—In the
combined safety database (n=1414), new onset type 1 diabetes
mellitus without an alternative etiology occurred in 1 patient
(<0.1%). For type 1 diabetes mellitus, initiate insulin as
indicated and withhold Imfinzi until clinically stable
- Hypophysitis—In the combined safety
database (n=1414), hypopituitarism leading to adrenal insufficiency
and diabetes insipidus occurred in 1 patient (<0.1%). Administer
corticosteroids and hormone replacement as clinically
indicated
Other Immune-Mediated Adverse Reactions
- Imfinzi has caused immune-mediated
rash. Other immune-related adverse reactions, including aseptic
meningitis, hemolytic anemia, immune thrombocytopenic purpura,
myocarditis, myositis, nephritis, and ocular inflammatory toxicity
including uveitis and keratitis, have occurred in ≤1.0% of patients
treated with Imfinzi
- Immune-mediated rash or dermatitis—In
the combined safety database (n=1414), immune-mediated rash or
dermatitis occurred in 220 patients (15.6%) and 4 patients (0.3%)
developed vitiligo. In Study 1 (n=182), 20 patients (11.0%)
developed rash, including 1 Grade 3 case (0.5%). Patients should be
monitored for signs and symptoms of rash or dermatitis. Administer
corticosteroids if indicated. Withhold Imfinzi for Grade 3 rash or
dermatitis or Grade 2 rash or dermatitis lasting >1 week.
Permanently discontinue Imfinzi in patients with Grade 4 rash or
dermatitis
- Immune thrombocytopenic purpura—In the
combined safety database (n=1414), 1 fatal case (<0.1%) of
immune thrombocytopenic purpura occurred. Monitor patients for
signs and symptoms of immune thrombocytopenic purpura
- Nephritis—In the combined safety
database (n=1414), immune-mediated nephritis occurred in 3 patients
(0.2%), including 2 Grade 3 cases (0.1%). Monitor patients for
abnormal renal function tests prior to and during each cycle of
Imfinzi. Administer corticosteroids for ≥Grade 2 nephritis
(creatinine >1.5X ULN). Withhold Imfinzi for Grade 2 nephritis;
permanently discontinue for ≥Grade 3 nephritis (creatinine >3X
ULN)
InfectionSevere infections, including sepsis, necrotizing
fasciitis, and osteomyelitis, occurred in patients receiving
Imfinzi. In the combined safety database (n=1414), infections
occurred in 531 patients (37.6%). In Study 1 (n=182), infections
occurred in 54 patients (29.7%). 11 patients (6.0%) experienced
Grade 3–4 infection and 5 patients (2.7%) were experiencing
infection at the time of death. 8 patients (4.4%) experienced
urinary tract infection, the most common ≥Grade 3 infection.
Monitor patients for signs and symptoms of infection and treat with
anti-infectives for suspected or confirmed infections. Withhold
Imfinzi for ≥Grade 3 infection.
Infusion-Related ReactionsIn the combined safety database
(n=1414), severe infusion-related reactions occurred in 26 patients
(1.8%). In Study 1 (n=182), infusion-related reactions occurred in
3 patients (1.6%). There were 5 Grade 3 (0.4%) and no Grade 4 or 5
reactions. Patients should be monitored for signs and symptoms of
infusion-related reactions. Interrupt or slow the rate of infusion
for Grade 1–2 infusion-related reactions and permanently
discontinue for Grade 3–4 infusion-related reactions.
Embryo-Fetal ToxicityBased on its mechanism of action and
data from animal studies, Imfinzi can cause fetal harm when
administered to a pregnant woman. There are no data on the use of
Imfinzi in pregnant women. Advise pregnant women of the potential
risk to a fetus and advise women of reproductive potential to use
effective contraception during treatment and for at least 3 months
after the last dose of Imfinzi.
Nursing MothersThere is no information regarding the
presence of Imfinzi in human milk; however, because of the
potential for adverse reactions in breastfed infants from Imfinzi,
advise a lactating woman not to breastfeed during treatment and for
at least 3 months after the last dose.
Most Common Adverse Reactions
- The most common adverse reactions
(≥15%) were fatigue (39%), musculoskeletal pain (24%), constipation
(21%), decreased appetite (19%), nausea (16%), peripheral edema
(15%), and urinary tract infection (15%). The most common Grade 3
or 4 adverse reactions (≥3%) were fatigue, urinary tract infection,
musculoskeletal pain, abdominal pain, dehydration, and general
physical health deterioration
- Adverse reactions leading to
discontinuation of Imfinzi occurred in 3.3% of patients. Serious
adverse reactions occurred in 46% of patients. The most frequent
serious adverse reactions (>2%) were acute kidney injury (4.9%),
urinary tract infection (4.4%), musculoskeletal pain (4.4%), liver
injury (3.3%), general physical health deterioration (3.3%),
sepsis, abdominal pain, and pyrexia/tumor associated fever (2.7%
each)
The safety and effectiveness of Imfinzi have not been
established in pediatric patients.
Approved Uses
Imfinzi is indicated for the treatment of patients with locally
advanced or metastatic urothelial carcinoma who:
- have disease progression during or
following platinum-containing chemotherapy
- have disease progression within 12
months of neoadjuvant or adjuvant treatment with
platinum-containing chemotherapy
This indication is approved under accelerated approval based on
tumor response rate and duration of response. Continued approval
for this indication may be contingent upon verification and
description of clinical benefit in confirmatory trials.
Please see complete Prescribing
Information including Patient Information.
NOTES TO EDITORS
AstraZeneca/MedImmune key presentations
at the 2017 ASCO Annual Meeting
Lead author
Abstract title
Presentation details
DNA Damage Response (DDR)
Robson ME
OlympiAD: Phase III Trial ofOlaparib
Monotherapy VersusChemotherapy for Patients withHER2-Negative
Metastatic BreastCancer and a Germline BRCAMutation
Oral
Plenary Session Including the Science of
Oncology Award and LectureSunday June 4th, 1:00-4:00 p.m.
CDTPresentation Time: 3:10-3:25 p.m. CDT
Location: Hall B1Abstract #LBA4
Friedlander M
Health-Related Quality of Life(HRQOL) and
Patient-CenteredOutcomes Support the ClinicalBenefit of
Prolongation ofProgression-Free Survival withOlaparib Maintenance
FollowingChemotherapy in Patients withGermline BRCA-mutated
Platinum-SensitiveRelapsed Serous Ovarian Cancer:SOLO-2 Phase III
Trial
Oral
Gynecologic Cancer
Friday June 2nd, 3:00-6:00 p.m.
CDTPresentation Time: 5:12-5:24 p.m. CDT
Location: S406
Abstract #5507
Liu JF
Overall Survival and
UpdatedProgression-Free Survival Resultsfrom a Randomized Phase II
trialComparing the Combination ofOlaparib and Cediranib
AgainstOlaparib Alone in RecurrentPlatinum-Sensitive Ovarian
Cancer
Poster
Gynecologic OncologySaturday June 3rd,
1:15-4:45 p.m. CDTLocation: Hall AAbstract #5535
Poster #357
Alexander BM
Phase I study of AZD1775 withRadiation
Therapy and Temozolomidein Patients with Newly
DiagnosedGlioblastoma (GBM) and Evaluation ofIntratumoral Drug
Distribution inPatients with Recurrent GBM
Oral
Central Nervous System TumorsSunday June
4th, 8:00-11:00 a.m. CDT
Presentation Time: 9:24-9:36 a.m.
CDTLocation: S100aAbstract #2005
Mendez E
A Phase I Clinical Trial of AZD1775
inCombination with Neoadjuvant WeeklyCisplatin and Docetaxel in
BorderlineResectable Head and NeckSquamous Cell Carcinoma
Poster
Head and Neck CancerMonday June 5th,
1:45-4:45 p.m. CDTLocation: Hall A
Abstract #6034Poster #22
Tumor Drivers & Resistance
Garassino M
CNS Response to Osimertinib inPatients
with T790M-PositiveAdvanced Non-Small Cell LungCancer: Data from a
RandomizedPhase III Trial (AURA3)
OralLung Cancer – Non-Small Cell MetastaticTuesday
June 6th, 9:45 a.m.-12:45 p.m. CDT
Presentation Time: 11:33-11:45 a.m.
CDTLocation: Hall D1Abstract #9005
Yang JC-H
Osimertinib for Patients
withLeptomeningeal Metastases fromEGFR-Mutant Non-Small Cell
LungCancer: Updated Results from theBLOOM Study
Poster DiscussionCentral Nervous System TumorsMonday
June 5th, 1:15-4:45 p.m. CDT
Discussion time: 4:45-6:00 p.m. CDTPoster
Location: Hall A
Discussion Location: S404Abstract
#2020
Poster #262
Immuno-Oncology
Hahn NM
Updated Efficacy and Tolerability
ofDurvalumab in Locally Advanced orMetastatic Urothelial
Carcinoma
PosterGenitourinary (Nonprostate) CancerSunday June
4th, 8:00-11:30 a.m. CDTLocation: Hall AAbstract #4525
Poster #203
Balmanoukian A
Updated Safety and Clinical Activity
ofDurvalumab Monotherapy inPreviously-Treated patients with
StageIIIB/IV Non-Small Cell Lung Cancer
Poster
Lung Cancer – Non-Small Cell
Metastatic
Saturday June 3rd, 8:00-11:30 a.m.
CDTLocation: Hall AAbstract #9085
Poster #411
Streicher K
Increased CD73 and Reduced IFNGSignature
Expression in Relation toResponse Rates to Anti-PD-1(L1)Therapies
in EGFR-Mutant Non-SmallCell Lung Cancer.
Oral
Tumor BiologySunday June 4th, 8:00-11:00
a.m. CDTPresentation Time: 9:12-9:24 a.m. CDT
Location: S406
Abstract #11505
About
Lynparza™ (olaparib)Lynparza™ (olaparib)
was the first FDA-approved oral poly ADP-ribose polymerase (PARP)
inhibitor that may exploit tumor DNA damage response (DDR) pathway
deficiencies to preferentially kill cancer cells. Specifically, in
vitro studies have shown that olaparib-induced cytotoxicity may
involve inhibition of PARP enzymatic activity and increased
formation of PARP-DNA complex, resulting in disruption of cellular
homeostasis and cell death.
Lynparza is the foundation of AstraZeneca’s industry-leading
portfolio of compounds targeting DDR mechanisms in cancer
cells.
Lynparza tablets are currently being investigated in monotherapy
and in combinations in a range of tumor types including breast,
prostate and pancreatic cancer. Lynparza tablets are an
investigational formulation and are not FDA-approved for any
use.
About Tagrisso® (osimertinib)Tagrisso® (osimertinib)
40mg and 80mg once daily oral tablet has been approved in over 45
countries, including the US, EU, Japan and China, for patients with
EGFR T790M mutation-positive advanced non-small cell lung cancer
(NSCLC). Eligibility for treatment with Tagrisso is dependent
on confirmation that the EGFR T790M mutation is present in the
tumor.
Tagrisso is a third generation, irreversible EGFR tyrosine
kinase inhibitor designed to inhibit both EGFR sensitizing and EGFR
T790M resistance mutations and to have activity in the central
nervous system (CNS). Tagrisso is also being investigated in
the adjuvant and metastatic first-line settings, including in
patients with and without CNS metastases, in leptomeningeal
metastases, and in combination with other treatments.
About Imfinzi™ (durvalumab)Imfinzi™
(durvalumab, previously known as MEDI4736) is a human monoclonal
antibody directed against PD-L1, which blocks the interaction of
PD-L1 with PD-1 and CD80.
Durvalumab is also being tested in the first-line treatment of
patients with unresectable and metastatic bladder cancer as a
monotherapy and in combination with tremelimumab, a checkpoint
inhibitor that targets CTLA-4, as part of the DANUBE Phase III
trial, which had the last patient commenced dosing during the first
quarter of 2017 (global trial, excluding China). Additional
clinical trials are ongoing to investigate durvalumab as
monotherapy or in combination with tremelimumab in multiple solid
tumors and blood cancers.
About AstraZeneca in OncologyAstraZeneca has a
deep-rooted heritage in Oncology and offers a quickly growing
portfolio of new medicines that has the potential to transform
patients’ lives and the Company’s future. With at least six new
medicines to be launched between 2014 and 2020, and a broad
pipeline of small molecules and biologics in development, we are
committed to advance New Oncology as one of AstraZeneca’s five
Growth Platforms focused on lung, ovarian, breast and blood
cancers. In addition to our core capabilities, we actively pursue
innovative partnerships and investments that accelerate the
delivery of our strategy as illustrated by our investment in Acerta
Pharma in hematology.
By harnessing the power of four scientific platforms –
Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response
and Antibody Drug Conjugates – and by championing the development
of personalized combinations, AstraZeneca has the vision to
redefine cancer treatment and one day eliminate cancer as a cause
of death.
About MedImmuneMedImmune is the global biologics research
and development arm of AstraZeneca, a global, innovation-driven
biopharmaceutical business that focuses on the discovery,
development and commercialization of small molecule and biologic
prescription medicines. MedImmune is pioneering innovative research
and exploring novel pathways across Oncology; Respiratory,
Cardiovascular & Metabolic Diseases; and Infection and
Vaccines. The MedImmune headquarters is located in Gaithersburg,
MD, one of AstraZeneca’s three global R&D centers, with
additional sites in Cambridge, UK, and Mountain View, CA. For more
information, please visit www.medimmune.com.
About AstraZenecaAstraZeneca is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialization of prescription medicines,
primarily for the treatment of diseases in three main therapy areas
– Oncology, Cardiovascular & Metabolic Diseases and
Respiratory. The Company also is selectively active in the areas of
autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please visit
www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170526005307/en/
AstraZenecaMichele Meixell, +1 302-885-2677orAlexandra Engel +1
302-885-2677
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024